OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
15
Results
Show all
Save search
Copy query
Show results for
Unknown
(15)
Publication Date
Release Date
2021
(6)
2023
(3)
2022
(3)
2025
(1)
2020
(1)
2018
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Not available
S-EPMC5903999
|
biostudies-literature
Cite
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Not available
S-EPMC9132770
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592
|
biostudies-literature
Cite
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
Not available
S-EPMC7857407
|
biostudies-literature
Cite
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Not available
S-EPMC10208981
|
biostudies-literature
Cite
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Not available
S-EPMC7953461
|
biostudies-literature
Cite
Whole-genome sequencing reveals host factors underlying critical COVID-19.
Not available
S-EPMC9259496
|
biostudies-literature
Cite
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets